Replies to post #214558 on Biotech Values

[mcbio]

Allena Pharmaceuticals is taking the old Altus Drug for Hyperoxaluria and after what appears to be some post hoc analysis is moving it forward.

Not normally something to be confident about. Is there something in particular about the post hoc analysis that would give comfort about the lead drug moving forward? BTW, if memory serves I believe Altus was spun out of VRTX many years ago.

The founder was the same founder of the technology at Altus Alexey Margolin who successfully took another failed Altus drug (for Pancreatic Insufficiency) started a company and sold it (forget to who) they were approved 2 years ago according to the presentation (but took more than 1 review).

Would be interesting to know what type of sales that drug is doing. Based on CEO's bio (http://www.allenapharma.com/leadership-team ), I'm guessing that Alnara was the company that he started and sold to LLY in 2010 for the drug for pancreatic insufficiency.

Edit: I think their second drug (for Gout) is also from Altus! I am not sure about Allena now I liked Alexey and the Altus tech. Seemed they got some new IP which would have been a concern.

Not sure I'm following what you're saying here. Are you saying you're skeptical because the entire pipeline is tied to Altus?